Instadose Pharma (Instadose Pharma) Change In Receivables : $0.00 Mil (TTM As of Feb. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma Change In Receivables?

Instadose Pharma's change in receivables for the quarter that ended in Feb. 2022 was $0.00 Mil. It means Instadose Pharma's Accounts Receivable stayed the same from Nov. 2021 to Feb. 2022 .

Instadose Pharma's change in receivables for the fiscal year that ended in Nov. 2021 was $0.00 Mil. It means Instadose Pharma's Accounts Receivable stayed the same from Nov. 2020 to Nov. 2021 .

Instadose Pharma's Accounts Receivable for the quarter that ended in Feb. 2022 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Instadose Pharma's liquidation value for the three months ended in Feb. 2022 was $-8.09 Mil.

Instadose Pharma Change In Receivables Historical Data

The historical data trend for Instadose Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instadose Pharma Change In Receivables Chart

Instadose Pharma Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Change In Receivables

Get a 7-Day Free Trial

Instadose Pharma Quarterly Data
	May17	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Instadose Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Feb. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Instadose Pharma (OTCPK:INSD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Instadose Pharma's Days Sales Outstanding for the quarter that ended in Feb. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Instadose Pharma's accounts receivable are only considered to be worth 75% of book value:

Instadose Pharma's liquidation value for the quarter that ended in Feb. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.004	-	8.089	+	0.75 * 0	+	0.5 * 0
=	-8.09

Instadose Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Instadose Pharma (Instadose Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6

Website

https://www.instadosepharma.com

Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.